Profile data is unavailable for this security.
About the company
TetraLogic Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics in oncology, infectious diseases and autoimmune diseases. The Company's segment is the identification and development of novel small molecule therapies in oncology and infectious diseases. The Company has approximately two clinical-stage product candidates in development, such as birinapant and SHAPE. SHAPE is the Company's histone deacetylase (HDAC) inhibitor that it is developing for topical use for the treatment of early-stage cutaneous T-cell lymphoma (CTCL). The Company is also exploring studying SHAPE in alopecia areata, an autoimmune skin disease. SHAPE has been granted the United States orphan drug designation for CTCL. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases (SMAC)-mimetic, which leads to apoptosis or cell-death in damaged cells.
- Revenue in USD (TTM)0.00
- Net income in USD-40.72m
- Incorporated2003
- Employees29.00
- LocationTetraLogic Pharmaceuticals Corp343 Phoenixville PikePO Box 1305MALVERN 19355United StatesUSA
- Phone+1 (610) 889-9900
- Fax+1 (610) 889-9994
- Websitehttps://infinitepaving.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shengtai Pharmaceutical Inc | -100.00bn | -100.00bn | 10.00 | 733.00 | -- | 0.00 | -- | -- | -- | -- | -- | 6.71 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.343 | -- | 0.5848 | -- | -- | -- | -- | -- | -- | -- |
| Refocus Group Inc | 0.00 | -4.77m | 20.00 | 4.00 | -- | -- | -- | -- | -0.1961 | -0.1961 | 0.00 | 0.0574 | 0.00 | 0.00 | -- | 0.00 | -140.63 | -- | -205.65 | -- | -- | -- | -- | -- | 3.08 | -44.01 | 0.00 | -- | -- | -- | 32.59 | -- | -- | -- |
| Altrazeal Life Sciences Inc | 568.75k | -2.20m | 20.00 | 7.00 | -- | 0.00 | -- | 0.00004 | -0.1093 | -0.1093 | 0.0282 | 0.2154 | 0.0689 | 0.3993 | 3.38 | -- | -26.67 | -45.42 | -36.70 | -77.20 | 67.69 | 62.08 | -387.26 | -423.73 | 1.29 | -3.56 | 0.1618 | -- | 62.04 | 14.12 | 56.52 | -- | -44.14 | -- |
| Tetralogic Pharmaceuticals Corp | 0.00 | -40.72m | 20.00 | 29.00 | -- | -- | -- | -- | -1.64 | -1.64 | 0.00 | -1.25 | 0.00 | -- | -- | 0.00 | -59.95 | -- | -69.46 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -38.28 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Herculis Partners SAas of 31 Jan 2020 | 90.00k | 0.00% |
